valsartan has been researched along with Cytokine Release Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerji, S; Mehrpour, O; Nakhaee, S; Shirazi, FM | 1 |
| Ferrara, F; La Porta, R; Vitiello, A | 1 |
2 other study(ies) available for valsartan and Cytokine Release Syndrome
| Article | Year |
|---|---|
Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Host-Pathogen Interactions; Humans; Losartan; Pandemics; Pneumonia, Viral; Prognosis; SARS-CoV-2; Severity of Illness Index; Telmisartan; Tomography, X-Ray Computed; Valsartan | 2020 |
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Biphenyl Compounds; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Combinations; Heart Failure; Homeostasis; Humans; Inflammation; Models, Theoretical; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan; World Health Organization | 2021 |